News
News
Study by Zoltan Oltvai Examines Targeted Therapy Resistance in AML
Tuesday, April 20, 2021
The professor of Pathology & Laboratory Medicine and his colleagues identified a mutation in the isocitrate dehydrogenase 1 (IDH1) gene attributed to relapse, drug resistance and disease progression in patients treated with IDH1 inhibitors for acute myeloid leukemia (AML). The findings published in Cold Spring Harbor Molecular Case Studies demonstrate a new mode to assess alternative targeted therapies to improve outcomes for those fighting the disease.